SCM Lifescience Balance Sheet Health
Financial Health criteria checks 4/6
SCM Lifescience has a total shareholder equity of ₩17.4B and total debt of ₩3.6B, which brings its debt-to-equity ratio to 20.9%. Its total assets and total liabilities are ₩22.3B and ₩5.0B respectively.
Key information
20.9%
Debt to equity ratio
₩3.63b
Debt
Interest coverage ratio | n/a |
Cash | ₩9.51b |
Equity | ₩17.35b |
Total liabilities | ₩4.97b |
Total assets | ₩22.32b |
Financial Position Analysis
Short Term Liabilities: A298060's short term assets (₩10.4B) exceed its short term liabilities (₩1.2B).
Long Term Liabilities: A298060's short term assets (₩10.4B) exceed its long term liabilities (₩3.8B).
Debt to Equity History and Analysis
Debt Level: A298060 has more cash than its total debt.
Reducing Debt: A298060 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A298060 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A298060 has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.7% each year.